F-1/A: WORK Medical Technology Group LTD Files Amendment No. 8 to Form F-1 for Initial Public Offering

WORK Medical Technology Group LTD, a Cayman Islands holding company operating through its PRC subsidiaries, has filed Amendment No. 8 to its Form F-1 registration statement for an initial public offering of 3,000,000 Ordinary Shares.

Summary

• WORK Medical Technology Group LTD, a Cayman Islands holding company, is planning an initial public offering (IPO) of 3,000,000 Ordinary Shares.
• The company conducts its operations through PRC subsidiaries, primarily Work (Hangzhou) Medical Treatment Equipment Co., Ltd.
• The expected IPO price range is $4.00 to $5.00 per share.
• The company has applied to list its Ordinary Shares on the Nasdaq Capital Market under the symbol 'WOK'.
• The offering is contingent upon final approval from Nasdaq for listing.
• The company is both an emerging growth company and a foreign private issuer, which allows it to comply with certain reduced public company reporting requirements.
• Investors will not directly hold equity interests in the PRC subsidiaries but rather in the Cayman Islands holding company.
• The company and its PRC subsidiaries are subject to legal and operational risks associated with being based in China.
• The company completed filing procedures with the CSRC on December 21, 2023.
• The company believes it is not required to obtain CSRC approval under the M&A Rules but is required to complete filing procedures with the CSRC under the Trial Administrative Measures.
• The company does not believe it is subject to cybersecurity review by the CAC.
• The company's auditor, WWC, P.C., is based in the U.S. and is registered with the PCAOB.
• The company may rely on dividends and other distributions on equity paid by the PRC subsidiaries for its cash and financing requirements.
• The principal amount of funds transferred among the PRC subsidiaries was $8,262,606 and $84,234 for the fiscal years ended September 30, 2023 and 2022, respectively.
• The company intends to use the net proceeds of the offering for upgrading production equipment, developing new products, marketing, patent purchases, and working capital.
• The underwriter has a 45-day option to purchase up to 15% of the Ordinary Shares offered to cover over-allotments.

Sentiment

Score: 5

Explanation: The document presents both positive aspects (e.g., growth strategies) and negative aspects (e.g., risks associated with operating in China, potential delisting). The financial results show a decline in revenue and net income, which tempers the overall sentiment. The sentiment is neutral.

Positives

• The company has completed the filing procedures with the CSRC.
• The company's auditor is based in the U.S. and is registered with the PCAOB.
• The company has a defined plan for the use of proceeds from the IPO.
• The company has a wide distribution network.

Negatives

• The company is subject to legal and operational risks associated with being based in China.
• The company's Ordinary Shares may be delisted under the Holding Foreign Companies Accountable Act if the PCAOB is unable to inspect the company's auditors.
• The company may experience difficulties in effecting service of legal process, enforcing foreign judgments or bringing actions in China against the company or its directors and officers.
• The company relies on dividends and other distributions on equity paid by the PRC subsidiaries to fund offshore cash and financing requirements and any limitation on the ability of the PRC subsidiaries to make remittance to pay dividends to the company could limit the company's ability to access cash generated by the operations of those entities.
• The company may be treated as a resident enterprise for PRC tax purposes under the PRC Enterprise Income Tax Law, and the company may therefore be subject to PRC income tax on its global income.
• The company is subject to a variety of fire protection laws that could be costly for the company to comply with, and the company could incur liability if it fails to comply with such laws, which could adversely affect the Group as a whole.
• The company is subject to a variety of construction laws, and the company could incur liability if it fails to comply with such laws, which could adversely affect its operations.
• The company's rights to use its leased warehouses, a parking area, one R&D production space, and two offices could be challenged by governmental authorities, due to the lessors failure to obtain the property ownership certificate as required by law, and its rights to use the leased collectively managed construction land could be challenged by governmental authorities, due to the lessors failure to comply with legal procedures related to land lease.

Risks

• Changes in political and economic policies of the PRC government or in relations between China and the United States may materially and adversely affect the PRC subsidiaries and the company's business, financial condition and results of operations.
• There are uncertainties regarding the interpretation and enforcement of PRC laws, rules and regulations.
• The PRC government exerts substantial influence over the manner in which the PRC subsidiaries conduct their business activities.
• Additional compliance procedures may be required in connection with this offering, due to the promulgation of the new filing-based administrative rules for overseas offering and listing by domestic companies in China.
• You may experience difficulties in effecting service of legal process, enforcing foreign judgments or bringing actions in China against the company or its directors and officers named in the prospectus based on foreign laws.
• The company's Ordinary Shares may be delisted under the Holding Foreign Companies Accountable Act if the PCAOB is unable to inspect the company's auditors.
• Failure to maintain the quality and safety of the PRC subsidiaries products could have a material and adverse effect on the PRC subsidiaries and the company's reputation, financial condition and results of operations.
• The PRC subsidiaries may experience significant liability claims or complaints from customers, doctors and patients, litigation and regulatory investigations and proceedings, such as claiming in relation to medical device safety, or adverse publicity involving their products, which could adversely affect the PRC subsidiaries and the company's financial condition and results of operations.
• The PRC subsidiaries face the risk of fluctuations in the cost, availability and quality of their raw materials, which could adversely affect their results of operations, and thus, adversely affect the Group as a whole.
• The PRC subsidiaries do not have long term contracts with their suppliers and the suppliers can reduce order quantities or terminate sales to the PRC subsidiaries at any time.
• The PRC subsidiaries industry is intensely competitive. The PRC subsidiaries may face competition from, and they may be unable to compete successfully against, new entrants and established companies with greater resources.
• If the PRC subsidiaries fail to identify, acquire and develop other products, they may be unable to grow their business.
• The PRC subsidiaries international sales are subject to a variety of risks that could adversely affect their profitability and operating results, which may adversely affect the profitability and operating results of the Group.
• If the PRC subsidiaries fail to timely renew their medical device licenses or registration certificates, it could adversely affect the PRC subsidiaries and the company's reputation, financial condition and results of operations.
• An active trading market for the company's Ordinary Shares may not develop and the trading price for the company's Ordinary Shares may fluctuate significantly.
• Nasdaq may apply additional and more stringent criteria for the company's initial and continued listing because the company plan to have a small public offering and insiders will hold a large portion of the company's listed securities.
• The trading price of the company's Ordinary Shares may be volatile, which could result in substantial losses to investors.
• Because the initial public offering price is substantially higher than the net tangible book value per share, you will experience immediate and substantial dilution.
• The company may experience extreme stock price volatility unrelated to its actual or expected operating performance, financial condition or prospects, making it difficult for prospective investors to assess the rapidly changing value of the company's Ordinary Shares.

Future Outlook

The company intends to use the net proceeds of this offering for (i) upgrading production equipment and increasing production capacity, (ii) developing masks, other medical consumables and medical devices, (iii) marketing, (iv) patent purchases and (v) working capital and other general corporate purposes.

Industry Context

The medical device industry is intensely competitive and includes thousands of companies, both domestically and internationally. As more medical device companies seek to outsource more of the design, prototyping and manufacturing of their products, the PRC subsidiaries will face increasing competitive pressures to grow their business in order to maintain their competitive position, and they may encounter competition from, and lose customers to, other companies with design, technological and manufacturing capabilities similar to theirs.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• To make a detailed comparison, specific financial metrics of comparible companies would be required.
• Without this information, a detailed comparison to industry standards is not possible.

Related Party Transactions

• The company has engaged in several related party transactions, including loans to and from related parties, sales to related parties, and rent income from related parties.
• The company has made advances to related parties for the company's initial public offering costs, including legal fees and accounting fees.

Stakeholder Impact

• Shareholders face risks associated with operating in China and potential delisting.
• Employees may be affected by changes in the company's financial performance and strategic direction.
• Customers may benefit from the company's plans to upgrade production equipment and develop new products.

Next Steps

• Obtain final approval from Nasdaq for listing.
• Complete the IPO and begin trading on the Nasdaq Capital Market.
• Implement the planned use of proceeds for business development and growth.

Key Dates

Keywords

IPO, Initial Public Offering, Medical Devices, PRC Subsidiaries, China, Nasdaq, Ordinary Shares, CSRC, PCAOB, WOK